A business in context

ENGN research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-09-08 · 8005 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 8-K · Current report

    Report date 2026-08-11 · 0001193125-26-344559 · Items 8.01,9.01

  2. 8-K · Current report

    Report date 2026-07-17 · 0001193125-26-307795 · Items 7.01,9.01

  3. 8-K · Current report

    Report date 2026-07-15 · 0001193125-26-305418 · Items 5.02,7.01,9.01

  4. 8-K/A · Current report

    Report date 2026-06-16 · 0001193125-26-275815 · Items 2.05,5.02

  5. 4 · Ownership change

    Report date 2026-06-16 · 0000929638-26-002263

  6. 4 · Ownership change

    Report date 2026-06-16 · 0000929638-26-002262

  7. 4 · Ownership change

    Report date 2026-06-16 · 0000929638-26-002261

  8. 4 · Ownership change

    Report date 2026-06-16 · 0000929638-26-002260

  9. 4 · Ownership change

    Report date 2026-06-16 · 0000929638-26-002259

  10. 4 · Ownership change

    Report date 2026-06-16 · 0000929638-26-002258

  11. 4 · Ownership change

    Report date 2026-06-16 · 0000929638-26-002257

  12. 4 · Ownership change

    Report date 2026-06-16 · 0000929638-26-002256

  13. 10-Q · Quarterly report

    Report date 2026-04-30 · 0001193125-26-270386

  14. 8-K · Current report

    Report date 2026-06-13 · 0001193125-26-270384 · Items 2.02,2.05,5.02,7.01,8.01,9.01

  15. 8-K · Current report

    Report date 2026-06-09 · 0001193125-26-265830 · Items 5.07,9.01

  16. DEF 14A · Proxy statement

    Report date 2026-06-09 · 0001140361-26-020024

  17. 8-K · Current report

    Report date 2026-05-05 · 0001193125-26-210316 · Items 5.02,7.01,8.01,9.01

  18. 8-K · Current report

    Report date 2026-04-07 · 0001193125-26-149597 · Items 5.03,7.01,9.01

  19. 8-K · Current report

    Report date 2026-03-09 · 0001193125-26-097546 · Items 1.01,1.02,9.01

  20. 10-Q · Quarterly report

    Report date 2026-01-31 · 0001193125-26-097541

  21. 8-K · Current report

    Report date 2026-03-09 · 0001193125-26-097534 · Items 2.02,9.01

  22. 10-K/A · Annual report

    Report date 2025-10-31 · 0001193125-26-059409

  23. 8-K · Current report

    Report date 2026-01-20 · 0001193125-26-017945 · Items 1.01,2.03,3.02,9.01

  24. 8-K · Current report

    Report date 2026-01-20 · 0001193125-26-017226 · Items 7.01,9.01

  25. 10-K · Annual report

    Report date 2025-10-31 · 0001193125-25-328743

  26. 8-K · Current report

    Report date 2025-12-22 · 0001193125-25-328706 · Items 2.02,9.01

  27. 8-K · Current report

    Report date 2025-11-12 · 0001193125-25-283182 · Items 1.01,7.01,9.01

  28. 8-K · Current report

    Report date 2025-11-11 · 0001193125-25-275722 · Items 7.01,8.01,9.01

  29. 8-K · Current report

    Report date 2025-10-02 · 0001193125-25-228351 · Items 5.02

  30. 8-K/A · Current report

    Report date 2025-07-07 · 0001193125-25-228331 · Items 5.02

  31. 8-K · Current report

    Report date 2025-09-30 · 0001193125-25-224053 · Items 7.01,9.01

  32. 10-Q · Quarterly report

    Report date 2025-07-31 · 0000950170-25-114224

  33. 8-K · Current report

    Report date 2025-09-11 · 0000950170-25-114220 · Items 2.02,9.01

  34. 8-K · Current report

    Report date 2025-09-03 · 0000950170-25-112674 · Items 7.01,8.01,9.01

  35. 8-K · Current report

    Report date 2025-07-07 · 0000929638-25-002520 · Items 5.02,7.01,9.01

  36. 10-Q · Quarterly report

    Report date 2025-04-30 · 0000950170-25-085143

  37. 8-K · Current report

    Report date 2025-06-12 · 0000950170-25-085138 · Items 2.02,9.01

  38. 8-K · Current report

    Report date 2025-06-10 · 0000929638-25-002215 · Items 5.02,5.07,9.01

  39. 8-K · Current report

    Report date 2025-06-04 · 0000950170-25-083444 · Items 1.01,2.03,9.01

  40. 8-K · Current report

    Report date 2025-06-03 · 0000929638-25-002133 · Items 5.02,7.01,9.01

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-09-07 · 2026 Q2: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 0 transaction rows0PSale: 0 transaction rows0SGrant / award: 9 transaction rows9AExercise / conversion: 0 transaction rows0MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

9 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-06-16
2026-06-17
Astley-Sparke PhilipA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
31000.00.0
2026-06-16
2026-06-17
BRUNK GERALD AA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
31000.00.0
2026-06-16
2026-06-17
Glickman Richard MA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
31000.00.0
2026-06-16
2026-06-17
Grossman WilliamA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
200000.00.0
2026-06-16
2026-06-17
Grossman WilliamA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
31000.00.0
2026-06-16
2026-06-17
HASTINGS PAUL JA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
31000.00.0
2026-06-16
2026-06-17
Heffernan Michael ThomasA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
31000.00.0
2026-06-16
2026-06-17
Joustra WouterA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
31000.00.0
2026-06-16
2026-06-17
Zoth Lota S.A · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
31000.00.0

Identity & relationships

Wikidata structured data · retrieved 2026-09-07 · 1611 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0001980845enGene Therapeutics Inc.

No parent relationship is available in this import; this is not proof of independence.

No verified LEI join available.

GLEIF legal entity reference data · retrieved 2026-09-07 · 1177 checked identities; 0 unavailable records

Search names and former names
  • enGene Holdings Inc. · former SEC name · 2023-06-14 to 2026-03-09

Revenue in constant purchasing power

USD revenue expressed in 2026-07 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

No USD annual revenue periods with complete CPI coverage are available. Non-USD statements are not converted with U.S. CPI.

Bureau of Labor Statistics · retrieved 2026-09-08 · 9 selected series; gaps remain missing

Explore the CPI history ↗